ConductScience.org, home

Paper41449459

Advanced nanotechnology in enhancing immune checkpoint inhibitors (ICIs) for head and neck cancer therapy.

Jafari Z and 4 others. Cell Commun Signal, 2025. Cited by 1 paper, by iCite.

Cite this record

ConductScience Library. Advanced nanotechnology in enhancing immune checkpoint inhibitors (ICIs) for head and neck cancer therapy. Papers, record 41449459. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41449459

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Advanced nanotechnology in enhancing immune checkpoint inhibitors (ICIs) for head and neck cancer therapy.
PubMed
Journal
Cell Commun Signal
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
1
iCite
Revised in PubMed
2026-10-15
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Jafari ZZahrahttps://orcid.org/0009-0005-3285-0784
2Raoufi AAtiehhttps://orcid.org/0000-0002-1029-751X
3Athari SSSeyyed Shamsadinhttps://orcid.org/0000-0002-6355-6378
4Bahramkiya SSara
5Jafari DDavoodhttps://orcid.org/0000-0002-7822-5096

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Head and Neck NeoplasmsMajor topic
Immune Checkpoint InhibitorsMajor topic
Nanoparticle Drug Delivery SystemMajor topic
NanomedicineMajor topic
NanoparticlesMajor topic
Antineoplastic Combined Chemotherapy Protocols
Tumor Microenvironment
Immunity, Mucosal
Tumor Escape
Humans
Animals
Radiation Tolerance
Chemoradiotherapy
Photothermal Therapy
Photochemotherapy

Source PubMed

Download CSV of topics

References189

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
132792853Insights into Nanomedicine for Immunotherapeutics in Squamous Cell Carcinoma of the head and neck.Int J Biol Sci2020https://conductscience.org/library/papers/32792853PubMed
234305619Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives.Front Pharmacol2021https://conductscience.org/library/papers/34305619PubMed
332467567Nanomedicine and cancer immunotherapy.Acta Pharmacol Sin2020https://conductscience.org/library/papers/32467567PubMed
435551240Enhancing CRISPR/Cas gene editing through modulating cellular mechanical properties for cancer therapy.Nat Nanotechnol2022https://conductscience.org/library/papers/35551240PubMed
539474549Therapeutic Host Anticancer Immune Response through Photoimmunotherapy for Head and Neck Cancer May Overcome Resistance to Immune Checkpoint Inhibitors.Case Rep Oncol2024https://conductscience.org/library/papers/39474549PubMed
638335850Major and durable responses to photon and electron-beam palliative radiotherapies after immune-checkpoint inhibitors in head and neck cancer.Oral Oncol2024https://conductscience.org/library/papers/38335850PubMed
79784967CD28/B7 costimulation: a review.Crit Rev Immunol1998https://conductscience.org/library/papers/9784967PubMed
831741778Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer.Oncoimmunology2019https://conductscience.org/library/papers/31741778PubMed
929560283Controlled drug delivery vehicles for cancer treatment and their performance.Signal Transduct Target Ther2018https://conductscience.org/library/papers/29560283PubMed
1039501968Advanced Nanomaterials for Cancer Therapy: Gold, Silver, and Iron Oxide Nanoparticles in Oncological Applications.Adv Healthc Mater2025https://conductscience.org/library/papers/39501968PubMed
1132942725Nano-Enhanced Cancer Immunotherapy: Immunology Encounters Nanotechnology.Cells2020https://conductscience.org/library/papers/32942725PubMed
1240116158A Hybrid Manganese Nanoparticle Simultaneously Eliminates Cancer Stem Cells and Activates STING Pathway to Potentiate Cancer Immunotherapy.ACS Nano2025https://conductscience.org/library/papers/40116158PubMed
1315176068Solid-state solubility influences encapsulation and release of hydrophobic drugs from PLGA/PLA nanoparticles.J Pharm Sci2004https://conductscience.org/library/papers/15176068PubMed
1439335671Revolutionizing Cancer Treatment: Recent Advances in Immunotherapy.Biomedicines2024https://conductscience.org/library/papers/39335671PubMed
1536236192Temperature-Responsive Polymer Brush Coatings for Advanced Biomedical Applications.Polymers (Basel)2022https://conductscience.org/library/papers/36236192PubMed
1624328413Photodynamic therapy: oncologic horizons.Future Oncol2014https://conductscience.org/library/papers/24328413PubMed
1714556006Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance.Nat Immunol2003https://conductscience.org/library/papers/14556006PubMed
1831984810Stability issues and approaches to stabilised nanoparticles based drug delivery system.J Drug Target2020https://conductscience.org/library/papers/31984810PubMed
1940190094Nanosized Shikonin Disrupts Tumor-Cell Mismatch Repair and Synergizes with Manganese to Sensitize Squamous Carcinoma to Immunotherapy.ACS Nano2025https://conductscience.org/library/papers/40190094PubMed
2023480658Biomedical applications of graphene and graphene oxide.Acc Chem Res2013https://conductscience.org/library/papers/23480658PubMed

See all 189 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.

PMIDTitleJournalYearIn Papers
42654096Injectable Hydrogels for Breast Cancer Therapy: From Tumor Microenvironment-Responsive and Actively Targeted Drug Delivery to Immunotherapy and Theranostics.Pharmaceutics2026https://conductscience.org/library/papers/42654096

Source PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41449459

GET https://conductscience.org/api/papers/v1/41449459/references?page=2